These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Liscio JL; Mahoney MV; Hirsch EB Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591 [TBL] [Abstract][Full Text] [Related]
9. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam? Gentile I; Maraolo AE; Borgia G Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088 [No Abstract] [Full Text] [Related]
10. Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria. Gonzalez MD; McMullen AR; Wallace MA; Crotty MP; Ritchie DJ; Burnham CA Ann Lab Med; 2017 Mar; 37(2):174-176. PubMed ID: 28029009 [No Abstract] [Full Text] [Related]
11. Newer Intravenous Antibiotics in the Intensive Care Unit: Ceftaroline, Ceftolozane-Tazobactam, and Ceftazidime-Avibactam. Connor KA AACN Adv Crit Care; 2016 Oct; 27(4):353-357. PubMed ID: 27959289 [No Abstract] [Full Text] [Related]
12. New and Emerging Antibiotics for Complicated Intra-Abdominal Infections. Durand CR; Alsharhan M; Willett KC Am J Ther; 2017; 24(6):e763-e769. PubMed ID: 26796653 [TBL] [Abstract][Full Text] [Related]
13. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. Sader HS; Castanheira M; Mendes RE; Flamm RK; Farrell DJ; Jones RN Antimicrob Agents Chemother; 2015; 59(6):3656-9. PubMed ID: 25845861 [TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579 [TBL] [Abstract][Full Text] [Related]
15. Fraile-Ribot PA; Mulet X; Cabot G; Del Barrio-Tofiño E; Juan C; Pérez JL; Oliver A Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674059 [TBL] [Abstract][Full Text] [Related]
16. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015. Sader HS; Castanheira M; Flamm RK Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649 [TBL] [Abstract][Full Text] [Related]
18. [Clinical aspects of severe infections caused by antibiotic-resistant Gram-negative bacteria. The Empire strikes back?]. Sinkó J Orv Hetil; 2017 Oct; 158(39):1528-1534. PubMed ID: 28942664 [TBL] [Abstract][Full Text] [Related]
19. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Farrell DJ; Sader HS; Flamm RK; Jones RN Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078 [TBL] [Abstract][Full Text] [Related]
20. Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Clinical Bacteria Isolated from Patients with Cancer. Hachem R; Reitzel R; Rolston K; Chaftari AM; Raad I Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115350 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]